Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.31M, +91.6% YoY · Filed Aug 14, 2026
Pmgc Holdings Inc. (ELAB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.3 million and a net loss of $2.9 million. Free cash flow was -$2.0 million. As of Jun 30, 2026 it held $18.8 million in cash and investments and $5.2 million in total debt.
Revenue
$1.31M
+91.6% vs prior quarter
Net income
$-2.94M
-423.0% vs year-ago quarter
Operating cash flow
$-1.99M
-47.6% vs year-ago quarter
Free cash flow
$-2.02M
+39.7% vs prior quarter
EPS
$-0.07
Dividend per share
None
Shares outstanding
8.10M
+445.2% vs year-ago quarter
Net cash
$13.63M
Q2 FY2026
Operating margin
-769.0%
Q3 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELAB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newport Beach, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1840563
- Former names
- Elevai Labs Inc. (until Nov 27, 2024); Reactive Medical Labs Inc. (until Oct 14, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $681,994 | $304,136 | $285,948 | — |
| Operating income | — | — | — | -$2.2M | — |
| Net income | -$2.9M | -$5.0M | -$3.0M | -$2.6M | -$562,355 |
| Operating cash flow | -$2.0M | -$3.0M | -$1.8M | -$1.5M | -$1.3M |
| Free cash flow | -$2.0M | -$3.3M | -$2.1M | -$1.6M | — |
| Total assets | $36.6M | $26.0M | $12.9M | $14.9M | $9.4M |
| Total liabilities | $19.8M | $13.4M | $5.0M | $6.4M | $326,301 |
| Stockholders' equity | $16.7M | $12.6M | $7.8M | $8.5M | $9.0M |
| Cash and investments | $18.8M | $15.1M | $6.0M | $804,070 | $624,838 |
| Total debt | $5.2M | $2.6M | $1.2M | $1.2M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Sep 2, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Aug 27, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 273 Pmgc Holdings Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.